Literature DB >> 27033548

Complement and microglia mediate early synapse loss in Alzheimer mouse models.

Victoria F Beja-Glasser1, Bianca M Nfonoyim1, Soyon Hong1, Arnaud Frouin1, Shaomin Li2, Saranya Ramakrishnan1, Katherine M Merry1, Qiaoqiao Shi2, Arnon Rosenthal3,4,5, Ben A Barres6, Cynthia A Lemere2, Dennis J Selkoe2,7, Beth Stevens1,8.   

Abstract

Synapse loss in Alzheimer's disease (AD) correlates with cognitive decline. Involvement of microglia and complement in AD has been attributed to neuroinflammation, prominent late in disease. Here we show in mouse models that complement and microglia mediate synaptic loss early in AD. C1q, the initiating protein of the classical complement cascade, is increased and associated with synapses before overt plaque deposition. Inhibition of C1q, C3, or the microglial complement receptor CR3 reduces the number of phagocytic microglia, as well as the extent of early synapse loss. C1q is necessary for the toxic effects of soluble β-amyloid (Aβ) oligomers on synapses and hippocampal long-term potentiation. Finally, microglia in adult brains engulf synaptic material in a CR3-dependent process when exposed to soluble Aβ oligomers. Together, these findings suggest that the complement-dependent pathway and microglia that prune excess synapses in development are inappropriately activated and mediate synapse loss in AD.
Copyright © 2016, American Association for the Advancement of Science.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27033548      PMCID: PMC5094372          DOI: 10.1126/science.aad8373

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  29 in total

Review 1.  Alzheimer's disease is a synaptic failure.

Authors:  Dennis J Selkoe
Journal:  Science       Date:  2002-10-25       Impact factor: 47.728

2.  Synchronized formation and remodeling of postsynaptic densities: long-term visualization of hippocampal neurons expressing postsynaptic density proteins tagged with green fluorescent protein.

Authors:  Tatsuhiko Ebihara; Izumi Kawabata; Shinichi Usui; Kenji Sobue; Shigeo Okabe
Journal:  J Neurosci       Date:  2003-03-15       Impact factor: 6.167

3.  Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment.

Authors:  Stephen W Scheff; Douglas A Price; Frederick A Schmitt; Elliott J Mufson
Journal:  Neurobiol Aging       Date:  2005-11-09       Impact factor: 4.673

4.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

5.  High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation.

Authors:  L Mucke; E Masliah; G Q Yu; M Mallory; E M Rockenstein; G Tatsuno; K Hu; D Kholodenko; K Johnson-Wood; L McConlogue
Journal:  J Neurosci       Date:  2000-06-01       Impact factor: 6.167

6.  Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment.

Authors:  S W Scheff; D A Price; F A Schmitt; S T DeKosky; E J Mufson
Journal:  Neurology       Date:  2007-05-01       Impact factor: 9.910

7.  Many neuronal and behavioral impairments in transgenic mouse models of Alzheimer's disease are independent of caspase cleavage of the amyloid precursor protein.

Authors:  Julie A Harris; Nino Devidze; Brian Halabisky; Iris Lo; Myo T Thwin; Gui-Qiu Yu; Dale E Bredesen; Eliezer Masliah; Lennart Mucke
Journal:  J Neurosci       Date:  2010-01-06       Impact factor: 6.167

8.  Classical MHCI molecules regulate retinogeniculate refinement and limit ocular dominance plasticity.

Authors:  Akash Datwani; Michael J McConnell; Patrick O Kanold; Kristina D Micheva; Brad Busse; Mehrdad Shamloo; Stephen J Smith; Carla J Shatz
Journal:  Neuron       Date:  2009-11-25       Impact factor: 17.173

9.  The classical complement cascade mediates CNS synapse elimination.

Authors:  Beth Stevens; Nicola J Allen; Luis E Vazquez; Gareth R Howell; Karen S Christopherson; Navid Nouri; Kristina D Micheva; Adrienne K Mehalow; Andrew D Huberman; Benjamin Stafford; Alexander Sher; Alan M Litke; John D Lambris; Stephen J Smith; Simon W M John; Ben A Barres
Journal:  Cell       Date:  2007-12-14       Impact factor: 41.582

10.  Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase.

Authors:  Joanna L Jankowsky; Daniel J Fadale; Jeffrey Anderson; Guilian M Xu; Victoria Gonzales; Nancy A Jenkins; Neal G Copeland; Michael K Lee; Linda H Younkin; Steven L Wagner; Steven G Younkin; David R Borchelt
Journal:  Hum Mol Genet       Date:  2003-11-25       Impact factor: 6.150

View more
  880 in total

1.  Alzheimer's Disease Risk Factor Pyk2 Mediates Amyloid-β-Induced Synaptic Dysfunction and Loss.

Authors:  Santiago V Salazar; Timothy O Cox; Suho Lee; A Harrison Brody; Annabel S Chyung; Laura T Haas; Stephen M Strittmatter
Journal:  J Neurosci       Date:  2018-12-05       Impact factor: 6.167

2.  Upregulation of Alzheimer's Disease Amyloid-β Protein Precursor in Astrocytes Both in vitro and in vivo.

Authors:  Yingxia Liang; Frank Raven; Joseph F Ward; Sherri Zhen; Siyi Zhang; Haoqi Sun; Sean J Miller; Se Hoon Choi; Rudolph E Tanzi; Can Zhang
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

Review 3.  Contributions of monocytes to nervous system disorders.

Authors:  Juan Mauricio Garré; Guang Yang
Journal:  J Mol Med (Berl)       Date:  2018-07-21       Impact factor: 4.599

Review 4.  Microglia and astrocyte dysfunction in parkinson's disease.

Authors:  Tae-In Kam; Jared T Hinkle; Ted M Dawson; Valina L Dawson
Journal:  Neurobiol Dis       Date:  2020-07-28       Impact factor: 5.996

5.  Rescue of Transgenic Alzheimer's Pathophysiology by Polymeric Cellular Prion Protein Antagonists.

Authors:  Erik C Gunther; Levi M Smith; Mikhail A Kostylev; Timothy O Cox; Adam C Kaufman; Suho Lee; Ewa Folta-Stogniew; George D Maynard; Ji Won Um; Massimiliano Stagi; Jacqueline K Heiss; Austin Stoner; Geoff P Noble; Hideyuki Takahashi; Laura T Haas; John S Schneekloth; Janie Merkel; Christopher Teran; Zahra K Naderi; Surachai Supattapone; Stephen M Strittmatter
Journal:  Cell Rep       Date:  2019-01-02       Impact factor: 9.423

6.  Complement-Dependent Synaptic Uptake and Cognitive Decline after Stroke and Reperfusion Therapy.

Authors:  Ali M Alawieh; E Farris Langley; Wuwei Feng; Alejandro M Spiotta; Stephen Tomlinson
Journal:  J Neurosci       Date:  2020-04-14       Impact factor: 6.167

Review 7.  Microglia in Alzheimer's disease.

Authors:  Heela Sarlus; Michael T Heneka
Journal:  J Clin Invest       Date:  2017-09-01       Impact factor: 14.808

8.  Complement Targets Newborn Retinal Ganglion Cells for Phagocytic Elimination by Microglia.

Authors:  Sarah R Anderson; Jianmin Zhang; Michael R Steele; Cesar O Romero; Amanda G Kautzman; Dorothy P Schafer; Monica L Vetter
Journal:  J Neurosci       Date:  2019-01-15       Impact factor: 6.167

Review 9.  Multitasking Microglia and Alzheimer's Disease: Diversity, Tools and Therapeutic Targets.

Authors:  Alexandra Grubman; Katja M Kanninen; Tarja Malm
Journal:  J Mol Neurosci       Date:  2016-09-22       Impact factor: 3.444

Review 10.  Sexual dimorphism in predisposition to Alzheimer's disease.

Authors:  Daniel W Fisher; David A Bennett; Hongxin Dong
Journal:  Neurobiol Aging       Date:  2018-04-17       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.